Amgen's Repatha drug shows 37% sales growth, targeting a huge cardiovascular market opportunity.

Jim Cramer highlights Amgen's drug Repatha as a major growth driver, with sales up 37% to $953 million in Q2 2026. The drug reduces heart attack and stroke risk by 20% and is gaining adoption among cardiologists and primary care doctors. Cramer believes Repatha's cardiovascular market potential rivals Eli Lilly's GLP-1 drugs, making it a significant opportunity for Amgen. The company raised its full-year revenue guidance, signaling strong confidence in Repatha's future growth.